| Literature DB >> 34321919 |
Yang Li1, Long Feng2, Xiaoying Zhang1, Lianjun Huang1, Jie Song1, Guoqing Chen1, Yu Zhang3, Chenggang Zhang4, Weiguang Li4,5, Zeguo Feng6.
Abstract
PURPOSE: Propofol is commonly used as an intravenous anesthetic in surgical patients. However, its usage is associated with adverse effects. Auxiliary medication can reduce the dose of intravenous anesthetics. Hence, we investigated whether vitamin C could lower propofol dosage in elderly patients undergoing total knee replacement surgery. PATIENTS AND METHODS: The trial was carried out in PLA General Hospital in Beijing, China. We enrolled patients aged ≥50 years who were undergoing unilateral total knee arthroplasty with total intravenous anesthesia combined with lumbar sciatic nerve block. The patients were randomly assigned to either the vitamin C (Vc) group (0.067 g/kg) or the control group (an equivalent dose of normal saline). Nerve block was done for all the patients before the general anesthesia. The same depth of anesthesia was maintained during the operation. We compared the propofol dosage and adverse events (eg hypotension) during anesthesia between the two groups. This study was registered with the Chinese Clinical Trial Registry, www.chictr.org.cn, number ChiCTR-TRC-16010112.Entities:
Keywords: elderly patients; general anesthesia; propofol; vitamin C
Year: 2021 PMID: 34321919 PMCID: PMC8302814 DOI: 10.2147/JPR.S319172
Source DB: PubMed Journal: J Pain Res ISSN: 1178-7090 Impact factor: 3.133
Figure 1Flowchart of the trail.
Patients’ Demographic Characteristics
| Variables | Control Group (n=21) | Vc Group (n=15) | |
|---|---|---|---|
| Sex, male | 1 | 2 | |
| Age, y, mean±SD | 67.2±5.7 | 69.1±7.4 | 0.406 |
| Weight, Kg, mean±SD | 65.2±7.7 | 66.7±7.4 | 0.552 |
| Height, cm, mean±SD | 157.6±8.1 | 161.8±6.2 | 0.552 |
| BMI, (IQR) | 26.8 (24.8, 28.3) | 26.8(23.4, 27.3) | 0.328 |
| Surgical side, R/L | 8/13 | 7/8 | |
| ASA classification, n (%) | |||
| I | 2 (9.5) | 1 (6.7) | |
| II | 17 (81.0) | 13 (86.6) | |
| III | 2 (9.5) | 1 (6.7) | |
| Comorbidities | |||
| Hypertension, n (%) | 9 (42.9) | 5 (33.3) | 0.563 |
| Coronary arterial disease, n (%) | 1 (4.8) | 2 (13.3) | 0.359 |
| Diabetes n (%) | 2 (9.5) | 0 (0) | 0.219 |
Intraoperative Clinical Data
| Variables | Control Group (n=21) | Vc Group (n=15) | |
|---|---|---|---|
| Time of induction, min, (IQR) | 3(2, 4) | 3(2,4) | 0.412 |
| Induction dose, mg, (IQR) | 90(80, 115) | 100(90,110) | 0.379 |
| Average induction dose, mg/kg/h, (IQR) | 32(24.6, 43.5) | 26.9(22.4, 39.7) | 0.344 |
| Average induction dose, mg/kg, mean±SD | 1.4±0.3 | 1.5±0.4 | 0.637 |
| Duration of anesthesia, min, (IQR) | 118(108.5, 130) | 110(96, 124) | 0.131 |
| Total infusion dose, mg, mean±SD | 888.6±232.7 | 704.3±188.6 | 0.016 |
| Average maintenance dose, mg/kg/h, mean±SD | 6.9±1.6 | 5.8±1.0 | 0.013 |
| Recover time, min, mean±SD | 11.2±2.5 | 12.8±2.7 | 0.072 |
Hemodynamics Data
| Variables | Control Group (n=21) | Vc Group (n=15) | |
|---|---|---|---|
| Baseline MAP, mmHg, mean±SD | 97.6±6.9 | 94.6±5.9 | 0.185 |
| MAP in the intubation, mmHg, mean±SD | 81.9±7.3 | 81.7±7.4 | 0.940 |
| MAP after 3 minutes of intubation, mmHg, mean±SD | 72.8±12.5 | 73.6±11.5 | 0.836 |
| MAP after 6 minutes of intubation, mmHg, mean±SD | 72.2±11.1 | 72.0±9.7 | 0.944 |
| MAP after 9 minutes of intubation, mmHg, (IQR) | 77.7(72.5, 83.3) | 74.3(66.7, 82.7) | 0.386 |
| Intraoperative hypotension, n (%) | 16(76.2%) | 9(60%) | 0.465 |